日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

IL-10R inhibition induces neutrophil tumoricidal activity.

IL-10R抑制可诱导中性粒细胞的杀瘤活性。

Khalil Danny N, Gomez Ricardo, Regev Amit, Samaan Fadi, Marouf Yacine, Budhu Sadna, Hirschhorn Daniel, Schulze Isabell, Lavery Jessica A, Ceglia Nicholas, Freeman Samuel S, Maltez Vivien I, Garcia Jaynia M, Suek Nathan, Weng Chien-Huan, Cabanski Christopher R, Monette Sebastien, Romin Yevgeniy, Li Yanyun, Chaligne Ronan, Yellin Michael J, Keler Tibor, Maurer Deena M, Flamar Anne-Laure, Morgado-Palacin Lucia, Mangarin Levi M, Harding James J, Park Wungki, Lyman Jaclyn P, Maddock Stephen, O'Hara Mark H, Abou-Alfa Ghassan K, Vonderheide Robert H, O'Reilly Eileen M, Germain Ronald N, Wolchok Jedd D, Merghoub Taha

Clinical and Translational Results from PORTER, a Multicohort Phase I Platform Trial of Combination Immunotherapy in Metastatic Castration-Resistant Prostate Cancer

PORTER研究的临床和转化结果:一项针对转移性去势抵抗性前列腺癌的联合免疫疗法多队列I期平台试验

Galsky, Matthew D; Autio, Karen A; Cabanski, Christopher R; Wentzel, Kristopher; Graff, Julie N; Friedlander, Terence W; Howes, Timothy R; Shotts, Kristin M; Densmore, Julie; Spasic, Marko; Da Silva, Diane M; Chen, Richard O; Lata, Jennifer; Skolnik, Jeffrey; Keler, Tibor; Yellin, Michael J; LaVallee, Theresa M; Fairchild, Justin; Boffo, Silvia; O'Donnell-Tormey, Jill; Dugan, Ute; Bhardwaj, Nina; Subudhi, Sumit K; Fong, Lawrence

CD27 Agonist Antibodies Mediate Clinical Responses through Intratumoral Stimulation in B-cell Malignancies: Multicenter RiVa Trial

CD27激动剂抗体通过肿瘤内刺激介导B细胞恶性肿瘤的临床反应:多中心RiVa试验

Buermann, Lara E; Stanton, Louise; Rose-Zerilli, Matthew J J; Thorne, Kerensa; Coleman, Adam; Turaj, Anna H; Caddy, Joshua; Wignall, Christopher; Keyworth, Nicole; Konn, Zoe; McKay, Pamela; Osborne, Wendy; Linton, Kim; Medd, Patrick; Lown, Robert; Davies, Andrew J; Johnson, Peter W M; Al-Shamkhani, Aymen; Cragg, Mark S; Collins, Graham P; Keler, Tibor; Yellin, Michael; Gentles, Andrew J; Griffiths, Gareth; Lim, Sean H

TMOD-40. Genetic drivers shape tumor phenotype and composition of the tumor microenvironment in syngeneic mouse models of glioblastoma

TMOD-40。遗传驱动因素塑造胶质母细胞瘤同源小鼠模型中的肿瘤表型和肿瘤微环境组成。

Mathew, Divij; Ohri, Nitin; Ngiow, Shin Foong; Halmos, Balazs; Wumesh, K C; Garg, Madhur; Levsky, Jeffrey M; Cheng, Haiying; Gucalp, Rasim A; Bodner, William Raymond; Kabarriti, Rafi; Gutierrez-Chavez, Claudia; Zakharia, Adel; Kalnicki, Shalom; Keler, Tibor; Yellin, Michael; Minn, Andy J; Maity, Amit; Giles, Josephine R; Guha, Chandan; Wherry, E John; Lu, Zhongyan; Parsons, Emily; Richard, Stephanie A; Alba, Camille; Sukumar, Gauthaman; Rosenberger, John; Zhang, Xijun; Burgess, Timothy; Agan, Brian; Dalgard, Clifton; Pollett, Simon; Malloy, Allison M; Pyczek, Joanna; Snelling, Shannon; Lun, Xueqing; Ahn, Bo Young; Seo, Heewon; Yu, Miranda; Quail, Daniela; Morrissy, A Sorana; Chan, Jennifer A

A Phase I Trial of Atezolizumab and Varlilumab in Combination With Radiation in Patients With Metastatic NSCLC

一项评估阿特珠单抗和伐利鲁单抗联合放疗治疗转移性非小细胞肺癌患者的I期临床试验

Malhotra, Jyoti; Lin, Yong; Patel, Malini; Yellin, Michael J; Zachariah, Emmanuel; Krier, Curtis; Saxena, Ankit; Jabbour, Salma K

Pattern recognition receptor agonists in pathogen vaccines mediate antitumor T-cell cross-priming

病原体疫苗中的模式识别受体激动剂介导抗肿瘤T细胞交叉启动

Aleynick, Mark; Svensson-Arvelund, Judit; Pantsulaia, Gvantsa; Kim, Kristy; Rose, Samuel A; Upadhyay, Ranjan; Yellin, Michael; Marsh, Henry; Oreper, Daniel; Jhunjhunwala, Suchit; Moussion, Christine Carine; Merad, Miriam; Brown, Brian D; Brody, Joshua D

Expanding cross-presenting dendritic cells enhances oncolytic virotherapy and is critical for long-term anti-tumor immunity.

扩增交叉呈递树突状细胞可增强溶瘤病毒疗法,对长期抗肿瘤免疫至关重要

Svensson-Arvelund Judit, Cuadrado-Castano Sara, Pantsulaia Gvantsa, Kim Kristy, Aleynick Mark, Hammerich Linda, Upadhyay Ranjan, Yellin Michael, Marsh Henry, Oreper Daniel, Jhunjhunwala Suchit, Moussion Christine, Merad Miriam, Brown Brian D, García-Sastre Adolfo, Brody Joshua D

Safety, tolerability and efficacy of agonist anti-CD27 antibody (varlilumab) administered in combination with anti-PD-1 (nivolumab) in advanced solid tumors

激动剂抗CD27抗体(varlilumab)与抗PD-1抗体(nivolumab)联合治疗晚期实体瘤的安全性、耐受性和疗效

Sanborn, Rachel E; Pishvaian, Michael J; Callahan, Margaret K; Weise, Amy; Sikic, Branimir I; Rahma, Osama; Cho, Daniel C; Rizvi, Naiyer A; Sznol, Mario; Lutzky, Jose; Bauman, Julie E; Bitting, Rhonda L; Starodub, Alexander; Jimeno, Antonio; Reardon, David A; Kaley, Thomas; Iwamoto, Fabio; Baehring, Joachim M; Subramaniam, Deepa S; Aragon-Ching, Jeanny B; Hawthorne, Thomas R; Rawls, Tracey; Yellin, Michael; Keler, Tibor

Safety and activity of varlilumab, a novel and first-in-class agonist anti-CD27 antibody, for hematologic malignancies

varlilumab(一种新型的、首创的抗CD27激动剂抗体)治疗血液系统恶性肿瘤的安全性和活性

Ansell, Stephen M; Flinn, Ian; Taylor, Matthew H; Sikic, Branimir I; Brody, Joshua; Nemunaitis, John; Feldman, Andrew; Hawthorne, Thomas R; Rawls, Tracey; Keler, Tibor; Yellin, Michael J

Anti-IP-10 antibody (BMS-936557) for ulcerative colitis: a phase II randomised study

抗IP-10抗体(BMS-936557)治疗溃疡性结肠炎:一项II期随机研究

Mayer, Lloyd; Sandborn, William J; Stepanov, Yuriy; Geboes, Karel; Hardi, Robert; Yellin, Michael; Tao, Xiaolu; Xu, Li An; Salter-Cid, Luisa; Gujrathi, Sheila; Aranda, Richard; Luo, Allison Y